Literature DB >> 16050564

Advances in the understanding of risk factors for ovarian cancer.

Christina A Bandera1.   

Abstract

The identification of risk factors for ovarian cancer is central to the goal of preventing deaths from this disease. Reproductive and hormonal history clearly modulate the risk of ovarian cancer. Continuous ovulation associated with nulliparity increases the likelihood of ovarian malignancy. Protective factors include conditions that suspend ovulation, such as pregnancy, lactation and oral contraceptive use. Hereditary syndromes account for 10% of ovarian cancer cases. The breast ovarian cancer syndrome is caused by mutations in the BRCA1 and BRCA2 genes and is associated with an 11-40% risk of developing ovarian cancer. The hereditary nonpolyposis colorectal cancer syndrome (HNPCC, or Lynch II) is caused by mutations in DNA mismatch repair genes and carries a 12% risk of ovarian cancer. Due to a lack of adequate screening techniques, women with BRCA1, BRCA2 or HNPCC mutations should consider prophylactic removal of the ovaries and fallopian tubes when childbearing is complete. Genetic polymorphisms are hereditary genetic variations that may act in concert with other genetic, hormonal or environmental factors to potentiate the risk of ovarian cancer. Finally, ovarian cancer risk is altered by environmental and behavioral factors. Further study of the risk factors for ovarian cancer is needed to develop effective preventive strategies.

Entities:  

Mesh:

Year:  2005        PMID: 16050564

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  14 in total

1.  Serum microRNA-145 as a novel biomarker in human ovarian cancer.

Authors:  Huichao Liang; Zhipeng Jiang; Guie Xie; Yan Lu
Journal:  Tumour Biol       Date:  2015-02-27

2.  Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.

Authors:  Ivana Rizzuto; Renee F Behrens; Lesley A Smith
Journal:  Cochrane Database Syst Rev       Date:  2019-06-18

3.  Genetic variants in matrix metalloproteinase genes as disposition factors for ovarian cancer risk, survival, and clinical outcome.

Authors:  Yan Wang; Yuanqing Ye; Jie Lin; Larissa Meyer; Xifeng Wu; Karen Lu; Dong Liang
Journal:  Mol Carcinog       Date:  2013-11-19       Impact factor: 4.784

4.  Aberrant Beclin 1 expression is closely linked to carcinogenesis, differentiation, progression, and prognosis of ovarian epithelial carcinoma.

Authors:  Yang Zhao; Shuo Chen; Wen-feng Gou; Li-jun Xiao; Yasuo Takano; Hua-chuan Zheng
Journal:  Tumour Biol       Date:  2013-10-17

Review 5.  Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.

Authors:  Ivana Rizzuto; Renee F Behrens; Lesley A Smith
Journal:  Cochrane Database Syst Rev       Date:  2013-08-13

6.  The hMLH1 -93G>A Polymorphism and Risk of Ovarian Cancer in the Chinese Population.

Authors:  Leilei Niu; Shumin Li; Huamao Liang; Hua Li
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

7.  The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma.

Authors:  Shuo Chen; Wen-Feng Gou; Shuang Zhao; Zhe-Feng Niu; Yang Zhao; Yasuo Takano; Hua-Chuan Zheng
Journal:  BMC Cancer       Date:  2015-06-16       Impact factor: 4.430

8.  The essential roles of CCR7 in epithelial-to-mesenchymal transition induced by hypoxia in epithelial ovarian carcinomas.

Authors:  Shaomei Cheng; Lin Han; Jingyan Guo; Qing Yang; Jianfang Zhou; Xiangshan Yang
Journal:  Tumour Biol       Date:  2014-08-29

9.  The role of EMMPRIN expression in ovarian epithelial carcinomas.

Authors:  Yang Zhao; Shuo Chen; Wen-feng Gou; Zhe-feng Niu; Shuang Zhao; Li-jun Xiao; Yasuo Takano; Hua-chuan Zheng
Journal:  Cell Cycle       Date:  2013-08-08       Impact factor: 4.534

10.  BTG1 expression correlates with the pathogenesis and progression of ovarian carcinomas.

Authors:  Yang Zhao; Wen-Feng Gou; Shuo Chen; Yasuo Takano; Yin-Ling Xiu; Hua-Chuan Zheng
Journal:  Int J Mol Sci       Date:  2013-09-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.